The role of angiotensinconverting enzyme and angiotensin II receptors of the second type in the pathogenesis of proliferative diseases of the prostate
- Authors: Chibichyan M.B1, Chernogubova E.A2, Avetyan A.V1, Lapteva T.O3, Pavlenko I.A4, Kogan M.I1,2
-
Affiliations:
- Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation
- Federal State Budgetary Instituton of science “Federal Research Center Southern Scientific Center of the Russian Academy of Sciences”
- Federal State Budgetary Educational Institution “National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation “
- State budgetary institution of the Rostov region “Anatomical Pathology Bureau”
- Issue: No 1 (2022)
- Pages: 5-10
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/312783
- DOI: https://doi.org/10.18565/urology.2022.1.5-10
- ID: 312783
Cite item
Abstract
Full Text
About the authors
M. B Chibichyan
Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation
Email: michel_dept@mail.ru
Dr.Med.Sci., Associate Professor of the Department of Urology and Human Reproductive Health with the course of pediatric urology and andrology at the Faculty of Medicine and Pedagogy Rostov-on-Don, Russia
E. A Chernogubova
Federal State Budgetary Instituton of science “Federal Research Center Southern Scientific Center of the Russian Academy of Sciences”
Email: eachernogubova@mail.ru
Ph.D. senior researcher head Laboratory of Experimental Biology Rostov-on-Don, Russia
A. V Avetyan
Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation
Email: arsenalfvo@yandex.ru
Postgraduate student of the Department of Urology and Human Reproductive Health (with the course of pediatric urology and andrology) Rostov-on-Don, Russia
T. O Lapteva
Federal State Budgetary Educational Institution “National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation “
Email: lto-96@yandex.ru
pathologist of the highest category, head of the pathological department Rostov-on-Don, Russia
I. A Pavlenko
State budgetary institution of the Rostov region “Anatomical Pathology Bureau”
Email: foxxtrot@mail.ru
Biologist of the Department of High-Tech Diagnostic Methods of the State Budgetary !nstitution Rostov-on-Don, Russia
M. I Kogan
Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Health of the Russian Federation; Federal State Budgetary Instituton of science “Federal Research Center Southern Scientific Center of the Russian Academy of Sciences”
Email: dept_kogan@mail.ru
Dr.Med.Sci, Professor, Head of the Department of Urology and Human Reproductive Health (with the course of pediatric urology-andrology); Chief Researcher Laboratory of Experimental Biology Rostov-on-Don, Russia; Rostov-on-Don, Russia
References
- Phua T.J. The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective. Medicines. 2021,8:30. doi: 10.3390/medicines8060030
- Урология. Национальное руководство под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009.
- Аляев Ю.Г. Болезни предстательной железы. М.: ГЭОТАР-Медиа, 2015.
- Lee Ch.L. Kuo H.Ch. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts.Tzu Chi Medical Journal 2017;29(2):79-83. doi: 10.4103/tcmj.tcmj_20_17
- Cho A., Chughtai B., Te A.E. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2020;15:60-65. doi: 10.1007/s11884-019-00566-z
- Brawer M.K. Prostatic intraepithelial neoplasia: an overview. Rev Urol. 2005;7 (Suppl 3):S11-S18.
- Юрмазов З.А. Место ПИН в опухолевой патологии предстательной железы. Сибирский онкологический журнал. 2009;S1:224-225.
- Billis A., Magna L.A. !nflammatory atrophy of the prostate. Prevalence and significance. Arch. Pathol. Lab. Med. 2003;127(7):840-844. doi: 10.5858/2003-127-840-LAOTP.
- Trabzonlu L., Kulac I., Zheng Q., Hicks J.L., Haffner M.C., Nelson W.G., Sfanos K.S., Ertunc O. Lotan T.L., Heaphy C.M., Meeker A.K., Yegnasubramanian S., De Marzo A.M. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harb Perspect Med. 2019;9(4):a030403. doi: 10.1101/cshperspect.a030403.
- Чибичян М.Б., Коган М.И., Лаптева Т.О., Белоусов И.И., Иванов А.Г., Черногубова Е.А. Перипростатическое воспаление как фактор риска развития стеноза везико-уретрального анастомоза после радикальной простатэктомии. Урология. 2015;6:52-57.
- Karakiewicz P.І., Benayoun S., Begin L.R. Duclos A., Valiquette L., McCormack M., Benard F., Saad F., Perrotte P. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. ІМ J Clin Pract. 2007;61(3):425- 430. doi: 10.1111/j.1742-1241.2006.00905.x.
- de Bono J.S., Guo C., Gurel B., De Marzo A.M., Sfanos K.S., Mani R.S., Gil J., Drake C.G., Alimonti A. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20(8):455-469. doi: 10.1038/s41568-020-0267-9.
- Черногубова Е.А., Коган М.И. Ренин-ангиотензиновая система: роль в развитии и прогрессировании рака предстательной железы. Онкоурология. 2020; 16(4):181-190. doi: 10.17650/1726-9776-2020-16-4-181-190
- Santos R.A.S., Oudit G.Y., Verano-Braga T., Canta G., Steckelings U.M., Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316(5):H958-H970. doi: 10.1152/ajpheart.00723.2018.
- Кугаевская Е.В., Тимошенко О.С., Соловьева Н.И. Ангиотензин превращающий фермент: антигенные свойства доменов, роль в метаболизме пептида бета-амилоида и опухолевой прогрессии. Биомедицинская химия. 2015;61(3):301-311. doi: 10.18097/PBMC20156103301.
- Afsar B., Afsar R.E., Ertuglu L.A., Kuwabara M., Ortiz A., Covic A., Kanbay M. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. Clin Transl. Oncol. 2021;23:682-696. doi: 10.1007/s12094-020-02488-3
- ГОСТ Р 52379-2005 Национальный стандарт РФ «Надлежащая клиническая практика» (Good Clinical Practice; GCP), утвержден приказом Федерального агентства по техническомурегулированию и метрологии от 27.09.2005. № 232-ст.
- Голиков П.П., Николаева Н.Ю. Экспресс-метод определения активности ангиотензинпревращающего фермента в сыворотке крови. Клиническая лабораторная диагностика 1998;(1):11-13.
- Dabbs D.J. Diagnostic Immunohistochemistry. 2nd edit. Philadelphia, Churchill Livingstone: Elsevier, 2006; 828 p.
- Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера; 2002.
- Kryukova O.V., Tikhomirova V.E., Golukhova E.Z., Evdokimov V.V., Kalantarov G.F., Trakht I.N., Schwartz D.E., Dull R.O., Gusakov A.V., Uporov I.V., Kost O.A., Danilov S.M. Tissue Specificity of Human Angiotensin I-Converting Enzyme. PLoS One. 2015;10(11):e0143455. doi: 10.1371/journal.pone.0143455.
- Danilov S.M., Kadrev A.V., Kurilova O.V., Tikhomirova V.E., Kryukova O.V., Mamedov V.N., Kamalov D.M., Danilova N.V., Okhobotov D.A., Gayfullin N.M., Evdokimov V.V., Alekseev B.J., Kost O.A., Samokhodskaya L.M., Kamalov A.A. Tissue ACE phenotyping in prostate cancer. Oncotarget. 2019;10(59):6349-6361. doi: 10.18632/oncotarget.27276.
- Benigni A., Cassis P., Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247- 257. doi: 10.1002/emmm.201000080.
- Горбунова Е.Н., Давыдова Д.А., Крупин В.Н. Хроническое воспаление и фиброз как факторы риска простатических интраэпителиальных неоплазий и рака предстательной железы. Соврем технол мед. 2011;(1):79-83.
- Cai T., Santi R., Tamanini I., Galli I.C., Perletti G., Bjerklund Johansen T.E., Nesi G. Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.Int J Mol Sci. 2019;20(15):3833. doi: 10.3390/ijms20153833.
- Singh K.D., Karnik S. Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications. J Cell Signal 2016;1(2):111. doi: 10.4172/jcs.1000111
- Kaschin E., Unger T. Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function. Blood Press. 2003; 12(2):70-88. doi: 10.1080/08037050310001057 21.
- AbdAlla S., Lother H., Abdel-tawab A.M., Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001;276(43):39721- 39726. doi: 10.1074/jbc.M105253200.
- Dinh D.T., Frauman A.G., Somers G.R., Ohishi M., Zhou J., Casley D.J., Johnston C.I., Fabiani M.E. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol. 2002;196(2):213-219. doi: 10.1002/path.1021.
- Hunyady L., Catt K.J. Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II. Molecular Endocrinology. 2006;20:953-970. doi: 10.1210/me.2004-0536.
- Imai N., Hashimoto T., Kihara M., Yoshida S. Kawana I., Yazawa T., Kitamura H., Umemura S. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 2007;87(2):189-198. doi: 10.1038/labinvest.3700504.
- Septiadi I., Sugandiet S., Noegroho B.S., Tjahdjodjati, SafriadiF., Siregar S., Ricky A., Adi K., Sihombing A.T., Pramod S.V., Nasution R., Hernowo B. S. Angiotensin ii type-1 receptor (at1r) distribution in bph, high grade pin and adenocarcinoma of the prostate. Indonesian Journal of Urology. 2010;17(2): doi: 10.32421/juri.v17i2.348/
- Rodrigues-Ferreira S., Abdelkarim M., Dillenburg-Pilla P., Luissint A.C, di-Tommaso A., Deshayes F., Pontes C.L., Molina A., Cagnard N., Letourneur F., Morel M., Reis R.I., Casarini D.E., Terris B., Couraud P.O., Costa-Neto C.M., Di Benedetto M., Nahmias C. Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis. PLoS One. 2012;7(4):e35667. doi: 10.1371/journal.pone.0035667